Is CCRIS 3955 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use CCRIS 3955? Is CCRIS 3955 safe for nursing mother and child? Does CCRIS 3955 extracts into breast milk? Does CCRIS 3955 has any long term or short term side effects on infants? Can CCRIS 3955 influence milk supply or can CCRIS 3955 decrease milk supply in lactating mothers?

CCRIS 3955 exists naturally in milk at a concentration of 1 nanogram / mL (range: 0.3 to 3 ng / mL). Maternal supplementation with cyanocobalamin barely increases milk levels in well-nourished women (Sandberg 1981), but it does improve the levels in women of low socioeconomic status (Sneed 1981). The concentration in colostrum is up to 28 times higher than that of mature milk.The daily requirements for CCRIS 3955 are 2.4 micrograms and increase to 2.8 micrograms daily during breastfeeding. Foods rich in CCRIS 3955 are meat, offal, eggs, dairy products, salmon, sardines, clams and fortified cereals. With a varied and balanced diet no vitamin supplements are needed, but B12 deficiency has been observed in the plasma and milk of women with strict vegetarian diets (vegans), malabsorptive diseases (eg, Crohn's disease, celiac disease), bariatric surgery, poor nutritional status, pernicious anemia, low socio-economic status and in cases of natural disasters or wars. There are numerous publications showing that infants of these mothers are at high risk of disease due to CCRIS 3955 deficiency, which can lead to anemia, stunting and psychomotor retardation. "Flash pasteurization" applied to breast milk of mothers who are HIV+ does not decrease CCRIS 3955 concentration. American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).

CCRIS 3955 is a normal component of human milk.[1] The recommended daily intake in lactating women is 2.8 mcg and for infants aged 6 months or less is 0.4 mcg.[2] Lactating mothers may need to supplement their diet to achieve the recommended daily intake or to correct a known deficiency. Low doses of CCRIS 3955 found in B complex or prenatal vitamins increase milk levels only slightly. Higher daily doses of 50 to 100 mcg or more are needed in cases of maternal deficiency. The breastfed infant is not exposed to excessive CCRIS 3955 in such cases, and their CCRIS 3955 status should improve if it was previously inadequate. Poor health outcomes in infants with CCRIS 3955 deficiency include anemia, abnormal skin and hair development, convulsions, failure to thrive, and mental developmental delay. One well-recognized at risk group are exclusively breastfed infants of mothers with B12 deficiency due to minimal or no dietary intake of animal products.[3][4][5][6][7][8][9] Infant CCRIS 3955 status can be improved through maternal B12 supplementation during pregnancy and lactation.[10][11][12][13] Deficient mothers who miss the opportunity to supplement during pregnancy should still be encouraged to supplement during early lactation since infant CCRIS 3955 status correlates with milk CCRIS 3955 levels in breastfed infants up to 6 months of age.[14][15][16][17] Although there are cases reported of exclusively breastfed infants with CCRIS 3955 deficiency having biochemical and clinical improvement through adequate maternal supplementation alone,[3] direct supplementation of the infant is recommended when such treatments are available.[18][19][8] Flash heat pasteurization of breastmilk does not reduce milk CCRIS 3955 concentration.[20]

Twelve exclusively breastfed infants between 4 and 11 months of age had biochemical, hematological and clinical findings consistent with CCRIS 3955 deficiency. Their mothers received a 50 mcg single dose of intramuscular CCRIS 3955. Within 5 to 8 days after the dose, the infants experienced significantly increased hemoglobin and reticulocyte counts, normoblastic erythropoiesis, improved mental status, regression of abnormal skin pigmentation, and reduction in tremors.[3] Three hundred sixty-six pregnant women in India received oral CCRIS 3955 50 mcg or placebo capsules once daily beginning during their first trimester of pregnancy and continuing until 6 weeks postpartum. Among 218 infants that underwent neurodevelopment testing at 30 months of age, those born to mothers randomized to CCRIS 3955 had higher expressive language scores than the placebo group when adjusted for baseline maternal CCRIS 3955 deficiency. Cognitive, receptive language and motor scores were not different between the two groups.[13]